|Day Low/High||43.52 / 45.93|
|52 Wk Low/High||34.53 / 96.59|
First four subjects all with follow up beyond 12 weeks without any need for immunosuppression
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Study provides insight into long-term safety and durability of effect of contralateral-eye administration in subjects with childhood-onset blindness caused by RPE65 mutations
Cramer says you're in good shape with Dominion Resources, but he is avoiding Freeport-McMoRan.
Investors re-evaluated what stocks are actually worth and started buying, Cramer says.
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a weak on high relative volume candidate
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a pre-market mover with heavy volume candidate
Company also will provide an update on preclinical data on SPK-FVIII for the treatment of Hemophilia A
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a "perilous reversal" (up big yesterday but down big today) candidate
Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, AU, CKP, CMCT, CPLA, HURC, KSS, MTW, PH, PRTS, SAIC, UAN, ZOES Downgrades: DPLO, GNE, MRVC, VISI Initiations: ONCE Read on to get TheStreet Quant Ratings' detailed report:
Spark Adds New Program for One of the Leading Causes of Inherited Retinal Disease, Broadening Its Pipeline of Potential Treatments for Rare Blinding Conditions
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.